A Cross-Country Comparison of Rivaroxaban Spontaneous Adverse Event Reports and Concomitant Medicine Use with the Potential to Increase the Risk of Harm

Drug Safety

Volumn 37, Issue 12, 2014, Pages 1029-1035

  McDonald, Cameron J ^a   Kalisch Ellett, Lisa M ^a   Barratt, John D ^a   Caughey, Gillian E ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CLOPIDOGREL; CORTICOSTEROID; DILTIAZEM; DRONEDARONE; ENOXAPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; RIVAROXABAN; SEROTONIN UPTAKE INHIBITOR; VERAPAMIL; WARFARIN; ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADVERSE DRUG REACTION; AGED; ARTICLE; AUSTRALIA; BLEEDING; CANADA; CEREBROVASCULAR ACCIDENT; DEATH; DEEP VEIN THROMBOSIS; DRUG SURVEILLANCE PROGRAM; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUS SYSTEM HEMORRHAGE; PREVALENCE; UNITED STATES; VASCULAR HEMORRHAGE; COMPARATIVE STUDY; EPIDEMIOLOGY; MIDDLE AGED; ODDS RATIO; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTICOAGULANTS; AUSTRALIA; CANADA; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; ODDS RATIO; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; RIVAROXABAN; THIOPHENES; UNITED STATES;

EID: 84912522100     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0235-y     Document Type: Article

References (23)

1. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ. 2012;345:e7498.
2. Dentali F, Riva N, Crowther M, Turpie AGG, Lip GYH, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381–91.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011;365:883–91.
4. Adam SS, McDuffie JR, Ortel TL, Williams JJW. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012;157:796–807.
5. Cabral KP, Ansell J, Hylek EM. Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. J Thromb Haemost. 2011;9:441–9.
6. Thomas TF, Ganetsky V, Spinler SA. Rivaroxaban: an oral factor XA inhibitor. Clin Ther. 2013;35:4–27.
7. Davidson BL, Verheijen S, Lensing AA, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med. 2014;174:947–53.
8. Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. 5th ed. West Sussex: Wiley-Blackwell; 2012.
9. Australian Therapeutic Goods Administration. Database of Adverse Event Notifications (DAEN). 2013. http://www.tga.gov.au/safety/daen.htm. Accessed 2013 Jun 25.
10. Health Canada. Canada Vigilance Adverse Reaction Online Database. 2013. http://www.hc-sc.gc.ca/dhp-mps/medeff/databasdon/index-eng.php. Accessed 2013 Jul 1.
11. US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). 2013. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. Accessed 2013 Jun 25.
12. Therapeutic Guidelines Limited. Therapeutic guidelines: cardiovascular. Version 6. 2012. http://www.Tg.Org.Au/. Accessed 2013 Jul 25.
13. Australian medicines handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2013.
14. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483–6.
15. Egberts ACG, Meyboom RHB, Van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf. 2002;25:453–8.
16. McDonald CJ, Kalisch Ellett LM, Barratt JD, Caughey GE. An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Pharmacoepidemiol Drug Saf. Epub 2014 May 20. doi:10.1002/pds.3648.
17. Loke YK, Pradhan S, Yeong JK, Kwok CS. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. 2014;78(4):707–17.
18. Rawlins MD. A population approach to the rational use of therapeutic interventions. Clin Ther. 2013;35:1634–8.
19. Shah B, Hajjar E. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med. 2012;28:173–86.
20. Paton C, Ferrier N. SSRIs and gastrointestinal bleeding: gastroprotection may be justified in some patients. BMJ. 2005;331:529–30.
21. Alvarez-Requejo A, Carvajal A, Bégaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions: estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54:483–8.
22. Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf. 2003;12:271–81.
23. Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, Spettell CM, Brennan TA, Matlin OS, Avorn J, Choudhry NK. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation: quality and cost implications. Am J Med. Epub 2014 May 20. doi:10.1016/j.amjmed.2014.05.013.